The Epithelial Biochemistry Laboratory

Epithelial Biochemistry Laboratory

Epitope mapping of mAb806

The mAb 806 is a monoclonal antibody which acts againsts a mutant form of the EGF receptor variously called DeltaEGFR, de2-7 EGFR, or EGFRvIII. This receptor has been observed to be frequently highly expressed in human malignant gliomas and has been reported for cancers of the lung, breast, and prostate. The antibody does not bind to wild type EGF receptor and possesses significant antitumor activity. To gain a better idea of the mechanism of action of this antibody, we are attempting to determine the epitope of binding of mAb 806. Preliminary results indicate that the epitope is away from the novel splice site in the protein which is generated as a consequence of the mutation.

Lab members involved in the research:

Collaborators:

Members of Tumour Tagetting, Ludwig Institute for Cancer Research [provide details]
Members of JPSL, Ludwig Institute for Cancer Research [provide details]

Publications:
Johns TG, Stockert E, Ritter G, Jungbluth AA, Huang HJ, Cavenee WK, Smyth FE, Hall CM, Watson N, Nice EC, Gullick WJ, Old LJ, Burgess AW, Scott AM.
Novel monoclonal antibody specific for the de2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene.
Int J Cancer. 98: 398-408 (2002). [Medline entry]

Luwor RB, Johns TG, Murone C, Huang HJ, Cavenee WK, Ritter G, Old LJ, Burgess AW, Scott AM.
Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR.
Cancer Res. 61: 5355-5361 (2001). [Medline entry]